



July 17, 2023

Jeil Medical Corporation  
Dajung Lee  
RA Specialist  
702,703,704,705,706,804,805,807,812,815-ho, 55, Digital-ro  
34-gil, Guro-gu  
Seoul, 08378  
Korea, South

Re: K231441  
Trade/Device Name: ARIX Ankle System  
Regulation Number: 21 CFR 888.3030  
Regulation Name: Single/Multiple Component Metallic Bone Fixation Appliances And Accessories  
Regulatory Class: Class II  
Product Code: HRS, HWC  
Dated: May 18, 2023  
Received: May 18, 2023

Dear Dajung Lee:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

 Tejen D.  
Soni -S

For  
Shumaya Ali, M.P.H.  
Assistant Director  
DHT6C: Division of Restorative, Repair  
and Trauma Devices  
OHT6: Office of Orthopedic Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)

K231441

Device Name

ARIX Ankle System

Indications for Use (Describe)

The ARIX Ankle System is intended for use in internal fixation of the distal fibula.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*

## 510(k) Summary

[As required by 21 CFR 807.92]

### 1. Date Prepared [21 CFR 807.92(a)(a)]

17<sup>th</sup> June 2023

### 2. Submitter's Information [21 CFR 807.92(a)(1)]

- Name of Sponsor: Jeil Medical Corporation
  - Address: 702,703,704,705,706,804,805,807,812,815-ho, 55, Digital-ro 34-gil, Guro-gu, Seoul, 08378, Korea
- Contact Name: Dajung Lee / RA Specialist
  - Telephone No.: +82 2 850 3591
  - Fax No.: +82 2 850 3536
  - Email Address: dajunglee@jeilmed.co.kr
- Registration Number: 3004049923
- Name of Manufacturer: Same as Sponsor
  - Address: Same as Sponsor

### 3. Trade Name, Common Name, Classification [21 CFR 807.92(a)(2)]

- Trade Name; ARIX Ankle System
- Common Name; - Plate, Fixation, Bone (Primary)  
- Screw, Fixation, Bone
- Classification Name; - Single/multiple component metallic bone fixation appliances and Accessories (Primary)  
- Smooth or threaded metallic bone fixation fastener
- Classification Panel; Orthopedic
- Classification regulation; 21 CFR 888.3030 (Primary), 21 CFR 888.3040
- Product code; HRS (Primary), HWC
- Device Class; II

**4. Identification of Predicate Device(s) [21 CFR 807.92(a)(3)]**

The legally marketed device(s) to which substantial equivalence is claimed is/are:

Predicate Device	K081284 – VARIAX DISTAL FIBULA PLATE, HOWMEDICA OSTEONICS CORP.
Reference Device	K201656 – ARIX Elbow System, Jeil Medical Corporation

There are no significant differences between the subject device and the predicate devices that would adversely affect the use of the product. It is substantially equivalent to these devices in intended use and technological characteristics as internal fixation components.

**5. Description of the Device [21 CFR 807.92(a)(4)]**

The ARIX Ankle System is rigid fixation consisting of plates and screws in various configurations, shapes, and sizes.

The ARIX Ankle System is made of Unalloyed Titanium and Titanium Alloy (Ti-6Al-4V), which meet ASTM F67, Standard Specification for Unalloyed Titanium for Surgical Implant Applications, and ASTM F136, Standard Specification for Wrought Titanium-6 Aluminum-4 Vanadium ELI (Extra Low Interstitial) Alloy for Surgical Implant Applications, which are widely used for surgical implants with well-known biocompatibility.

**6. Indications for use [21 CFR 807.92(a)(5)]**

The ARIX Ankle System is intended for use in internal fixation of the distal fibula.

**7. Technological Characteristics [21 CFR 807.92(a)(6)]****ARIX Ankle System, Bone Plate:**

Based on the technological feature comparison, the subject device was found that there are no significant differences between the subject device and predicate device (K081284) that would adversely affect the use of the product and it is substantially equivalent to predicate device in technological characteristics.

**ARIX Ankle System, Bone Screw:**

ARIX Ankle System Bone Screws consist of reference devices with FDA-cleared and legally marketed devices in ARIX Elbow System (K201656).

**Non-Clinical Test Summary:**

Bench tests were conducted to ensure the safety and effectiveness of the device as well as to demonstrate substantial equivalence to the predicate device. The test results demonstrated that the subject device complies with the following standards:

- ASTM F382, Standard Specification and Test Method for Metallic Bone Plates
- ASTM F543, Standard Specification and Test Methods for Metallic Medical Bone Screws

The results of this testing indicate that the ARIX Ankle System is equivalent to predicate device.

**Clinical Test Summary**

No clinical studies were considered necessary and performed.

**8. Substantial Equivalence [21 CFR 807.92(b)(1) and 807.92]**

Based on the submitted information in this premarket notification, the subject device is substantially equivalent to the predicate device (K081284) in terms of:

- Intended use
- Technological characteristics (Design features, Material, Surface Treatment, Sterilization methods, Biocompatibility and Performance)

The subject device has met the performance, safety, and effectiveness of the device for its intended use.

**9. Conclusion [21 CFR 807.92(b)(3)]**

In all respects, the ARIX Ankle System is substantially equivalent to the legally marketed device (K081284). Above all, the subject device has equivalent intended use and technological characteristics. Further, nonclinical verification and validation to determine substantial equivalence provide additional evidence that subject device is substantially equivalent to the predicate device in terms of safety, efficacy, and performance.